Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Aug 26, 2019; 11(8): 548-564
Published online Aug 26, 2019. doi: 10.4252/wjsc.v11.i8.548
Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis in vitro and in vivo: From biological characteristics to therapeutic mechanisms
Fei Yin, Wen-Ying Wang, Wen-Hua Jiang
Fei Yin, Wen-Ying Wang, Wen-Hua Jiang, Department of Histology and Embryology, Basic Medical College of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Yin F wrote the manuscript; Wang WY collected the literature; Jiang WH revised the manuscript for important intellectual content.
Supported by the Natural Science Foundation of Jilin Province of China, No. 20190201010JC.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wen-Hua Jiang, MD, Adjunct Professor, Department of Histology and Embryology, Basic Medical College of Jilin University, No. 126 Xinmin Street, Changchun 130021, Jilin Province, China. jiangwenhua468@163.com
Telephone: +86-13604321909
Received: February 18, 2019
Peer-review started: February 20, 2019
First decision: June 5, 2019
Revised: June 26, 2019
Accepted: July 17, 2019
Article in press: July 17, 2019
Published online: August 26, 2019
Processing time: 189 Days and 2.1 Hours
Core Tip

Core tip: Liver fibrosis is a major global health problem, for which no efficient therapy is available. Cell therapy, particularly involving human umbilical cord mesenchymal stem cells (known as hUC-MSCs), represents a promising therapeutic strategy, based mainly on the cells’ paracrine effects, transdifferentiation capacity and immunomodulatory function. In this review, we discuss the characteristics of hUC-MSCs, focusing on the possible mechanisms of these cells to ameliorate liver fibrosis, based upon evidence from in vitro and in vivo studies as well as ongoing clinical trials. This review also includes a discussion of the current status of the field and its future prospects.